Episode notes
ASCO GI 2025 delivered big wins in gastrointestinal oncology. We highlight key findings, including nivolumab-plus-ipilimumab in MSI-H mCRC, encorafenib-based regimens for BRAF-mutant CRC, and innovative strategies in CAR-T therapies. Catch up on the most impactful data shaping the future of cancer care. Like what you hear? Download Curie from App Store for more in-depth insights in onlcology and general medicine.
Keywords
HealthcareMedicineDeepdivePodcastOncologyhematologyPhysicianUSAASCO GIGastrointestinal cancer